(Total Views: 581)
Posted On: 07/11/2020 5:22:26 PM
Post# of 154130
I don’t know where to get a copy of the study, but this is directly copied from Cytodyn’s website:
“ Leronlimab’s Clinical Trial Performance
CytoDyn has successfully completed a Phase 3 pivotal trial with Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients meeting its primary endpoint. 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with viral load suppression of < 50 cp/mL.”
It gives me confidence to see such a strong result, coupled with an even stronger safety profile. It’s also easier to take. Hope this helps until someone knows where to find the actual study.
“ Leronlimab’s Clinical Trial Performance
CytoDyn has successfully completed a Phase 3 pivotal trial with Leronlimab in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients meeting its primary endpoint. 81% of patients completing trial achieved HIV viral load suppression of < 50 cp/mL. Recent approved drugs for this population range from 43% after 24 weeks to 45% after 48 weeks with viral load suppression of < 50 cp/mL.”
It gives me confidence to see such a strong result, coupled with an even stronger safety profile. It’s also easier to take. Hope this helps until someone knows where to find the actual study.
(0)
(0)
